Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively (From 1/7/2009) and Prospectively (up to 31/12/2013) as First Line Treatment for Patients With Locally Advanced or Metastatic Colorectal Cancer (With or Without KRAS Mutation). Assessment of Toxicity, Compliance and Survival of Patients.
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2014
At a glance
- Drugs Antineoplastics (Primary) ; Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 21 Mar 2013 New trial record